<DOC>
	<DOC>NCT02231294</DOC>
	<brief_summary>Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions</brief_summary>
	<brief_title>The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients with idiopathic Parkinson's disease with tremor and/or depression requiring therapy with Sifrol® or change of therapy to Sifro®l and not under medication with neuroleptics were allowed to be observed during the study Patients who meet one or more of the general or specific contraindications mentioned in the Summary of Product Characteristics (SPC) for Sifrol® Patients under treatment with neuroleptics should not be observed during this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>